Skip to content
Open access

A Selective PanK3 Activator Restores Coenzyme A in Cellular and Mouse Models of Pantothenate Kinase-Associated Neurodegeneration.

Sep 2026 · Journal of Biological Chemistry · pp. 113567 · 0 citations · 51 references
Medicine

TL;DR

It is demonstrated that a lead VTAC compound, VTAC-2, restores CoA levels to wild-type levels both in cells and in mouse brain, making this compound an attractive candidate for clinical evaluation for the treatment of PKAN.

Abstract

Pantothenate kinase-associated neurodegeneration, PKAN, is a rare progressive neurodegenerative disorder associated with iron accumulation in the brain. The disease, which causes early immobility and often death by early adulthood, is caused by loss of function mutations in the human PANK2 gene, encoding a key enzyme in the biosynthesis of coenzyme A from pantothenic acid. To date, no disease-modifying therapy exists for PKAN, and current interventions are largely limited to symptomatic management. Herein we report the identification of a new class of direct activators of human PANK3, termed VTACs, designed to compensate for the loss of PANK2 function. Using cell and animal models of PanK2 deficiency, we demonstrate that a lead VTAC compound, VTAC-2, restores CoA levels to wild-type levels both in cells and in mouse brain. Moreover, the favorable physicochemical properties and oral bioavailability of VTAC-2 make this compound an attractive candidate for clinical evaluation for the treatment of PKAN.

Read PDF

Similar papers

Open access Oct 2026

PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12

How Roginolisib, a phosphoinositide 3-kinase delta specific inhibitor, locks the enzyme in an inactive conformation, providing high potency and specificity is reported, which results in reduced phosphatidylinositol 3,4,5-trisphosphate formation in tumour samples of CLL patients receiving Roginolisib.

O. Vadas, S. Tiede, Maria Chaouki et al. · 2 citations
Open access Oct 2026

Targeting HSPA1A with geranylgeranylacetone alleviates ADTKD-UMOD via suppression of endoplasmic reticulum stress and ferroptosis.

This study reveals a pathogenic ER-ferroptosis axis in ADTKD-UMOD, deepens the insight into the pathogenesis of ADTKD-UMOD, and provides a promising strategy for developing chaperone therapy with drug repurposing in genetic kidney diseases.

Wen Shi, Yan Yang, Xiang Wen et al. · 0 citations
Review Aug 2026

Pharmacological targeting of GCN5/PCAF (KAT2A/B): Current drug discovery strategies and translational potential.

This review outlines the structural features, functions and diverse roles of GCN5/PCAF in disease pathology, and proposes a framework for inhibitor development that integrates active-site engagement, pharmacophore modelling and function-driven targeting strategies to bridge the gap between early-stage discovery and tra...

Priyanka Pandey, Prajjval Mishra, Pritam Biswas et al. · 0 citations
Review Sep 2026

Unraveling the conundrum of multifaceted Pyruvate Kinase M2 in cancer: a potential therapeutic target with challenges in precision intervention.

Pyruvate kinase M2 (PKM2), a key glycolytic enzyme, plays a pivotal role in cancer-associated metabolic reprogramming and is frequently over-expressed in several malignancies. Beyond its metabolic activities, PKM2 exhibits numerous non-metabolic functions, mediated through a complex interplay of allosteric regulation,...

Trishit Banerjee, K. Bose · 0 citations
Open access Sep 2026

Gene therapy with doxycycline-controlled expression of human Kv1.1 reduces neuronal excitability and increases sociability of Scn2a-deficient mice

Overall, the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD is demonstrated.

Brody A. Deming, Jing-Liang Zhang, Iuliia Vitko et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.